Table 2. Summary of cases with treatment details.
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Reason to excise nipple-areola complex | Nipple tethering | Sub-areolar lump | Involved medial margin on vertical scar therapeutic mammoplasty – adjacent to nipple | Incidental cancer on duct excision for nipple discharge |
| Whole tumour size (in mm) | 60 | 50 | 60 | 17 and 6 |
| Further axillary treatment | No further treatment arm of POSNOC trial | Axillary Radiotherapy | Nil | Nil |
| Specimen weight (in gm) | 145 | 82 | 170 therapeutic mammoplasty 52 central excision |
8.5 total duct excision 35 central excision |
| Specimen dimensions (ML×AP×SI) mm | 86×75×40 | 77×25×65 | 80×70×45 40×35×62 |
45×30×15 55×40×43 |
| Surgical margins | Clear | Inferior margin focally involved with DCIS: re-excised – no further malignancy | NA (No further malignancy seen on central excision) | Clear |
| Closest peripheral margin | 1 mm (superior) | > 5 mm | >5 mm (medial) | 10 mm |
| Duration of surgery (in min) | 140 | 110 | 120 | 110 |
| Adjuvant chemotherapy | Yes | No. Oncotype RS 11 (NHS PREDICT 4% for third generation) | Yes, following vertical scar therapeutic mammoplasty | No |
| Adjuvant radiotherapy | Yes (breast with boost) – POSNOC no axillary RT | Yes (breast, axilla, SCF) | Yes (breast with boost) | Yes (breast) |
| Adjuvant endocrine therapy | Yes (Anastrozole) | Yes (Anastrozole) | Yes (Tamoxifen). Declined Zoladex, aromatase inhibitor and bisphosphonate | Yes (Tamoxifen) |
| Wound complication | Nil | Nil | Nil | Nil |
| Shoulder function recovery | Complete | Complete | Complete | Complete |
| Aesthetic outcome | Very good | Excellent | Excellent (right bigger than left pre radiotherapy) | Excellent |
ML, medio-lateral; AP: antero-posterior; SI, supero-inferior; NA: not applicable; RS, recurrence score; RT, radiotherapy